Jazz Pharmaceuticals plc vs Amphastar Pharmaceuticals, Inc.: Annual Revenue Growth Compared

Pharma Giants' Revenue Race: Jazz vs. Amphastar (2014-2023)

__timestampAmphastar Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20142104610001172875000
Thursday, January 1, 20152515190001324803000
Friday, January 1, 20162551650001487973000
Sunday, January 1, 20172401750001618693000
Monday, January 1, 20182946660001890922000
Tuesday, January 1, 20193223570002161761000
Wednesday, January 1, 20203498460002363567000
Friday, January 1, 20214377680003094238000
Saturday, January 1, 20224989870003659374000
Sunday, January 1, 20236443950003834204000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceuticals: Revenue Growth from 2014 to 2023

In the competitive landscape of pharmaceuticals, Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc. have shown distinct growth trajectories over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has consistently outpaced Amphastar in revenue, showcasing a robust growth of over 227%, reaching approximately $3.8 billion in 2023. In contrast, Amphastar, while starting from a smaller base, has demonstrated a commendable growth of over 206%, achieving around $644 million in the same year.

This period marks a significant era for both companies, with Jazz Pharmaceuticals leveraging its diverse portfolio to capture a larger market share, while Amphastar has steadily expanded its niche offerings. The data highlights the dynamic nature of the pharmaceutical industry, where strategic innovation and market adaptation are key to sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025